GVV858 Clinical Trials (2026): 1 Studies for Advanced CCNE1-amplified Solid Tumors & Advanced HR+/HER2- Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GVV858 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced CCNE1-amplified Solid Tumors & Advanced HR+/HER2- Breast Cancer) and 205 total planned enrollment. 1 GVV858 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07288359 (May 2031).
Where to Participate: All GVV858 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting GVV858trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TN | Tennessee Oncology PLLC | Nashville37203 | NCT07288359 | Map |
GVV858 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting GVV858 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | P1/P2 | Advanced HR+/HER2- Breast Cancer | 205 | Dec 2025 |
All GVV858 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | P1/P2 | recruiting | 205 | Novartis Pharmaceuticals | Dec 2025 |
GVV858 clinical trials: frequently asked questions
- How many GVV858 clinical trials are there?
- 1 GVV858 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GVV858 clinical trials recruiting in 2026?
- Yes — 1 GVV858 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is GVV858 being studied for?
- GVV858 is being studied for Advanced CCNE1-amplified Solid Tumors, Advanced HR+/HER2- Breast Cancer, Metastatic Castration-resistant Prostate Cancer. The trials are grouped by indication on this page.
- Who sponsors GVV858 clinical trials?
- The lead sponsor across the most GVV858 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GVV858as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: